A

fter concerns mounted a decade ago over financial ties between drug makers and doctors, various institutions took steps to limit potentially undue influence over medical research and practice. The federal government created a website where companies are required to report payments. And many academic medical centers and physician practices barred or restricted visits by drug sales reps.

But to what extent have these efforts made a difference?

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Recommended Stories

Sign up for our
Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine — delivered straight to your inbox every weekday afternoon.